# FACIAL SELECTIVITY OF THE SHARPLESS BROMINE CATALYZED AZIRIDINATION<sup>1</sup>


# Aaron C. Schmitt,<sup>2</sup> Catherine M. Smith, Eric A. Voight,<sup>2</sup> and George A. O'Doherty\*

Department of Chemistry, West Virginia University, Morgantown, WV 26506, USA. George.ODoherty@mail.wvu.edu

Abstract – A bromine catalyzed aziridination reaction has been applied to 7,7dibromo-3-norcarene, which resulted in a highly stereoselective route to *cis*-4,4dibromo-8-(toluene-4-sulfonyl)-8-azatricyclo[5.1.0.0]octane in a 46% yield. In order to confirm the stereochemistry of the aziridination reaction *trans*-4,4dibromo-8-(toluene-4-sulfonyl)-8-azatricyclo[5.1.0.0]octane and its diastereoisomer *cis*-4,4-dibromo-8-(toluene-4-sulfonyl)-8-azatricyclo[5.1.0.0]octane were prepared in a stereoselective manner from the corresponding *cis*- and *trans*-7,7-dibromo-3-norcarene epoxides (61 and 9.2% yields, respectively). These three routes offer stereochemical proof for the stereospecificity of the bromine-catalyzed aziridination of hindered alkenes.


# INTRODUCTION

As part of a project directed toward the synthesis of a substituted cocaine ring system, we hoped to synthesize the 6-substituted tropane (1) from cycloheptane (3) (Scheme 1). In turn we envisioned preparing 3 from either *cis*- or *trans*-aziridine (4a) and (4b) by two ring opening reactions.<sup>3,4</sup> In the course of our synthetic investigations of this route to the tropane ring system, we desired diastereoselective access to both the *cis*- and *trans*-aziridines (4a) and (4b). Thus we decided to investigate the various methods for the aziridination of cyclohexene (5). Herein, we describe two diastereoselective approaches for the selective synthesis of both *cis*- and *trans*-tosylaziridines (4a) and (4b). These results show the stereoselectivity of the bromine-catalyzed aziridination reaction and in turn lend credence to the mechanism proposed by Sharpless.<sup>5,6</sup>



## **RESULTS AND DISCUSSION**


The starting 7,7-dibromo-3-norcarene (**5**) was prepared by the dibromocyclopropanation procedure of cyclohexa-1,4-diene reported by Winstein.<sup>7</sup> Treatment of **5** with 1 equiv. chloramine-T and 10 mol % phenyltrimethylammonium perbromide<sup>8</sup> provided a 3:1 mixture of oxidized products, the *N*-tosylaziridine (**4**) (35 %) and bromo sulfonamide (**7**) (11.3 %) (Scheme 2). The bromo sulfonamide (**7**) was cleanly converted into the aziridine (**4**) upon treatment with NaH under anhydrous conditions (98 %). The mixture of **4** and **7** could similarly be converted into **4** with NaH, which greatly simplified the chromatographic purification of **4**. While the <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra clearly indicated the formation of **4** as a single diastereoisomer, we were unable to determine whether the *cis* or *trans* stereoisomer was formed.<sup>9</sup>



Scheme 2


Sharpless has suggested that the perbromide-catalyzed aziridination of alkenes occurs through a bromonium ion (**8a**) or (**8b**) that is subsequently trapped by chloramine-T (forming **9a** or **9b**) (Scheme 3). The intermediate *N*-chlorosulfonamide (**9**) is then reduced by a halide ion and cyclized to form the corresponding tosylaziridine (**4**). In terms of the stereochemistry of aziridination, two mechanistic questions still remained unanswered. Are the two diastereotopic bromonium ions (**8a**) and (**8b**) rapidly inter-converting? Which of the two diastereotopic bromonium ions reacts faster with chloramine-T? Thus, at the outset it was not clear to us whether a facially biased alkene would react under these conditions to form the sterically more hindered *cis*-aziridine (**4b**). Therefore, we decided to stereospecifically synthesize both the *cis*- and *trans-N*-

tosylaziridines (4a) and (4b) from stereo-defined starting materials and compare them to the material made from the Sharpless procedure.






Following virtually identical conditions, the known *trans*-epoxide  $(10)^{10}$  and *cis*-epoxide  $(11)^{11}$  were converted into diastereomeric azido-alcohols (12) and (13) (scheme 4).<sup>12</sup> Exposing the *trans*-epoxide (10) to excess NaN<sub>3</sub> (5 equiv.) and NH<sub>4</sub>Cl (1 equiv.) in refluxing methanol for 3 days produced the azido-alcohol (12) in an 82 % yield. Not surprisingly the diastereomeric epoxide (11) reacted more quickly with NaN<sub>3</sub> requiring only 3 h to give the corresponding azide (13) in the same yield (82 %).



Scheme 4

Once again under similar conditions the diastereomeric azido-alcohols (12) and (13) were transformed to the corresponding *cis*- and *trans N*-tosylaziridines (4a) and (4b), respectively (Scheme 5).<sup>13</sup> Exposure of 12 with triphenylphosphine in hot toluene (80 °C, 2 h) reductively cyclized 12 to an aziridine, which was protected *in situ* (TsCl/pyr, 0 °C) to form the *cis*-tosylaziridine (4a) (22 % yield). The low yield of 4a is presumably due to the steric hindrance of the *endo*-azide in 12. This is supported by the observation that exposure of the diastereomeric *exo*-azide (13) to the same PPh<sub>3</sub>/TsCl conditions provided the corresponding *trans*-tosylaziridine (4b) in a much higher 84 % yield. With authentic samples of 4a and 4b in hand it was evident that the *N*-tosylaziridine prepared from the bromine-catalyzed aziridination of 5 gives exclusively the *cis*-aziridine (4a). The <sup>1</sup>H NMR and <sup>13</sup>C NMR of 4a and 4b were clearly distinguishable and the crude <sup>1</sup>H NMR spectra from the bromine-catalyzed aziridination showed no evidence of the *trans*-aziridine (4b).

In conclusion, two diastereoselective routes to the *cis-N*-tosylaziridines (**4a**) (46 and 9.2 % yields) and one diastereoselective route to the *trans-N*-tosylaziridines (**4b**) (61 % yield) have been developed. These three routes help establish the stereospecificity of the bromine-catalyzed aziridination of hindered alkenes. In particular, this heavily biased substrate demonstrates the high degree that the initially formed bromonium ion can be trapped. Further use of these *N*-tosylaziridines for the synthesis of the tropane ring system will be reported in due course.



Scheme 5

#### EXPERIMENTAL

**General Methods:** Unless otherwise stated, all reactions were carried out under an atmosphere of nitrogen using oven-dried glassware and standard syringe/septa techniques. Analytical TLC was performed using precoated glass-backed plates (Whatman K6F 60A,  $F_{254}$ ) that were analyzed by fluorescence upon 254 nm irradiation or by staining with *p*-anisaldehyde, potassium permanganate, or phosphomolybdic acid stains. Liquid chromatography was performed using (flash chromatography) of the indicated solvent system on ICN reagent silica gel 60 (60-200 mesh). Ether and tetrahydrofuran were distilled from benzophenone and sodium metal. Dichloromethane and triethylamine were distilled from calcium hydride. Hexanes refers to the petroleum fraction bp 40-60 °C. Commercial reagents were used without purification unless otherwise noted. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on Varian 300 and 500 MHz spectrometers. Chemical shifts are reported relative to CDCl<sub>3</sub> ( $\delta$  7.26 ppm) or internal tetramethylsilane ( $\delta$  0.00 ppm) for <sup>1</sup>H spectrum and CDCl<sub>3</sub> ( $\delta$  77.0 ppm) for <sup>13</sup>C spectrum. Melting points are uncorrected. IR spectra were obtained on a Prospect MIDAC FT-IR spectrometer. HRMS spectrometric data was performed by the University of Minnesota Mass Spectrometry Laboratory. Combustion analyses were performed by M-H-W Laboratories, Phoenix, AZ.

*cis*-4,4-Dibromo-8-(toluene-4-sulfonyl)-8-azatricyclo[5.1.0.0<sup>3,5</sup>]octane (4a) Method A: To a solution of dibromide (5) (1.00 g, 3.96 mmol) dissolved in 20 mL of  $CH_3CN$  were added

phenyltrimethylammonium tribromide (PTAB) (0.142 g, 0.377 mmol) and Chloramine-T•3H<sub>2</sub>O (1.23 g, 4.35 mmol) at rt. The reaction was stired for 16 h, then diluted with CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and saturated NaHCO<sub>3</sub> solution (20 mL). The organic layer was separated, and the aqueous layer extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic layers were dried using Na<sub>2</sub>SO<sub>4</sub> and the solvent was removed in vacuo. The crude material was first run through a plug of silica gel using 0 - 50 % ether/hexanes to remove starting material and excess tosylamine, and then a column was run using 5-20 % EtOAc/hexanes. Isolated were 0.204 g (20 %) of dibromide (5), 0.476 g (28 %) of aziridine as a white crystalline solid, and 0.182 g (9.1 %) of open tribromide (7) as an off-white crystalline solid. R<sub>f</sub> 0.37 (20 % EtOAc/hexanes). mp 177 - 179 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.77 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 2.96 (m, 2H), 2.63 (m, 2H), 2.44 (s, 3H), 1.79 (m, 2H), 1.12 (ddd, J = 17.0, 5.0, 4.0 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 144.5, 135.1, 129.7, 127.7, 39.8, 37.0, 26.4, 21.7, 20.6. IR (neat): v 3044, 2996, 2922, 1596, 1547, 1494, 1393, 1163 cm<sup>-1</sup>. HRMS (CI) calcd for  $C_{14}H_{15}NO_2$  Br<sub>2</sub>S [M+H<sup>+</sup>] 419.9269, obsd 419.9279. Anal. Calcd for C<sub>14</sub>H<sub>15</sub>NO<sub>2</sub>Br<sub>2</sub>S: C, 39.93, H, 3.59. Found: C, 40.04, H, 3.77. Data for (+/-)-(1S\*,3R\*,4R\*,6R\*)-4-Methyl-N-(4,7,7-tribromobicyclo[4.1.0]hept-3-yl)**benzenesulfonamide (7).** R<sub>f</sub> 0.49 (20 % EtOAc/hexanes) <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  7.76 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 4.76 (d, J = 5.1 Hz, 1H), 3.94 (ddd, J = 16.2, 9.9, 6.0 Hz, 1H), 3.15 (m, 1H), 2.85 (ddd, J = 15.6, 9.9, 6.0 Hz, 1H), 2.56 (ddd, J = 15.3, 6.0, 1.8 Hz, 1H), 2.43 (s, 3H), 1.92 (m, 2H), 1.42 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 143.9, 137.0, 129.8, 127.4, 54.1, 50.3, 36.8, 32.9, 29.0, 28.8, 26.9, 21.7. IR (neat): v 3268, 3087, 2921, 1597, 1514, 1438, 1328, 1160, 1092 cm<sup>-1</sup>. HRMS (CI) calcd for C<sub>14</sub>H<sub>16</sub>NO<sub>2</sub>Br<sub>3</sub>S [M+H<sup>+</sup>] 499.8530, obsd 499.8559, calcd for [M+NH<sub>4</sub><sup>+</sup>] 516.8796, obsd 516.8772.

*cis*-4,4-Dibromo-8-(toluene-4-sulfonyl)-8-azatricyclo[5.1.0.0<sup>3,5</sup>]octane (4a) Method B: To a solution of tribromide (7) (143 mg, 0.286 mmol) in THF (2.8 mL) under nitrogen there was added 60 % NaH/mineral oil (24.3 mg, 0.632 mmol). After two hours the reaction was worked up by adding 10 % NaHCO<sub>3</sub> solution (10 mL) and was extracted with ethyl acetate (3 x 10 mL), The organic layers were combined and dried using Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The crude product required no further purification, yielding 117 mg (98 %).

(+/-) -( $1R^*$ , $3R^*$ , $4R^*$ , $6S^*$ )-4-Azido-7,7-dibromobicyclo[4.1.0]heptan-3-ol (12): To a solution of epoxide (10) (302 mg, 1.12 mmol) in methanol (3 mL) there were added NaN<sub>3</sub> (366 mg, 5.63 mmol) and ammonium chloride (69.7 mg, 1.30 mmol). The mixture was then heated to 70°C for 3 days. The reaction

was then diluted with ether (10 mL) and brine (10 mL). The layers were separated, and the aqueous layer was extracted with ether (3 x 10 mL). The organic layers were combined and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The remaining solid was purified by column chromatography (10 - 20 % EtOAc/hexanes) to yield 286 mg (82 %) of azido alcohol as a white solid, and 50 mg of epoxide starting material (17 %). R<sub>f</sub> 0.49 (20 % EtOAc/hexanes) mp 57-59 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.63 (ddd, J = 9.9, 9.9, 6.9 Hz, 1H), 3.23 (ddd, J = 12.5, 10.5, 5.4 Hz, 1H), 2.64 (ddd, J = 15.0, 9.6, 5.7 Hz, 1H), 2.45 (m, 1H), 2.25 (br s,1H), 2.09-1.81 (m, 3H), 1.49 (ddd, J = 15.0, 12.6, 4.2, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  69.4, 63.5, 37.5, 30.0, 29.3, 27.6, 26.9. HRMS calcd for C<sub>7</sub>H<sub>9</sub>N<sub>3</sub>OBr<sub>2</sub> [M+NH<sub>4</sub><sup>+</sup>] 326.9456, obsd 326.9453. IR (neat): v 3386, 3024, 2924, 2865, 2108, 1636, 1439, 1321, 1291, 1253, 1047 cm<sup>-1</sup>. Anal. Calcd for C<sub>7</sub>H<sub>9</sub>N<sub>3</sub>OBr<sub>2</sub>: C, 27.04, H, 2.92. Found: C, 27.30, H, 3.12.

(+/-)-(1R\*,3S\*,4S\*,6S\*)-4-Azido-7,7-dibromobicyclo[4.1.0]heptan-3-ol (13): To a solution of epoxide (11) (302 mg, 1.12 mmol) in methanol (2.2 mL) were added NaN<sub>3</sub> (363 mg, 5.58 mmol) and ammonium chloride (59.8 mg, 1.12 mmol). The mixture was then heated to 70 °C and allowed to stir for 3 h. The reaction was then diluted with ether (5 mL) and brine (10 mL). The aqueous layer was extracted with ether (3 x 10 mL) and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by column chromatography (10 - 20 % EtOAc/hexanes) to yield 286 mg (82 %) of azide as a white solid. R<sub>f</sub> 0.49 (20 % EtOAc/hexanes) mp 84 - 86 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.37-3.52 (m, 2H), 2.57 (ddd, *J* = 15.6, 9.9, 5.4 Hz, 1H), 2.47 (dd, *J* = 13.8, 6.3 Hz, 1H), 2.21 (br s, 1H), 1.85-2.04 (m, 2H), 1.50 (ddd, *J* = 14.7, 11.4, 3.6 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  70.0, 62.4, 37.3, 29.5, 28.0, 27.8, 27.1. IR (neat): v 3387, 2924, 2865, 2108, 1290, 1047 cm<sup>-1</sup>. HRMS calcd for C<sub>7</sub>H<sub>9</sub>N<sub>3</sub>OBr<sub>2</sub> [M + NH<sub>4</sub><sup>+</sup>] 326.9456, obsd 326.9435. Anal. Calcd for C<sub>7</sub>H<sub>9</sub>N<sub>3</sub>OBr<sub>2</sub>: C, 27.04, H, 2.92. Found: C, 27.25, H, 3.17.

*cis*-4,4-Dibromo-8-(toluene-4-sulfonyl)-8-azatricyclo[5.1.0.0<sup>3,5</sup>]octane (4a) Method C: To a solution of azide (12) (20.0 mg, 64.3 µmol) in toluene (2 mL) was added triphenylphosphine (20.1 mg, 76.6 µmol). The reaction was heated at 80 °C for 2 h until complete as judged by TLC analysis. The reaction was cooled to 0 °C and pyridine (10 µL, 0.13 mmol) then tosyl chloride (18.6 mg, 97.5 µmol) were added. The reaction was stirred overnight, then quenched with 10 % NaHCO<sub>3</sub> and extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were dried using Na<sub>2</sub>SO<sub>4</sub> and the solvent was removed in vacuo. The crude product was purified using column chromatography (10 - 20 % EtOAc/hexane). A white solid was isolated which had identical spectral data to compound (4a) yielding 6.0 mg of product (22 %).

*trans*-4,4-Dibromo-8-(toluene-4-sulfonyl)-8-azatricyclo[5.1.0.0<sup>3,5</sup>]octane (4b): To a solution of azide (13) (15.0 mg, 48.2 µmol) in toluene (2 mL) was added triphenylphosphine (15.2 mg, 58.0 µmol). The reaction was heated at 80 °C for 2 h until complete as judged by TLC analysis. The reaction was cooled to 0 °C and pyridine (10 µL, 0.13 mmol) then tosyl chloride (18.4 mg, 96.5 µmol) were added. The reaction was stirred overnight, then quenched with 10 % NaHCO<sub>3</sub> and extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were dried using Na<sub>2</sub>SO<sub>4</sub> and solvent was removed in vacuo. The crude product was purified using column chromatography (10 - 20 % EtOAc/hexane), yielding 17.0 mg of product as a white crystalline solid (84 %). R<sub>f</sub> 0.50 (20 % EtOAc/hexanes). mp 165 -167 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.79 (d, *J* = 8.5 Hz, 2H), 7.35 (d, *J* = 8.5 Hz, 2H), 2.88 (s, 2H), 2.46 (s, 3H), 2.33 (ddd, *J* = 16.5, 6.0, 2.5 Hz, 2H), 1.79 (dd, *J* = 16.0, 1.0 Hz, 2H), 1.70 (ddd, J = 5.0, 3.0, 1.0 2H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  144.5, 135.3, 129.8, 127.7, 38.5, 36.9, 22.8, 21.7, 18.8. IR (film): v 2920, 1596, 1428, 1323, 1159, 1091 cm<sup>-1</sup>. HRMS calcd for C<sub>14</sub>H<sub>15</sub>NO<sub>2</sub>Br<sub>2</sub>S [M+H]<sup>+</sup> 419.9269, obsd 419.9290.

### ACKNOWLEDGMENTS

We thank the Arnold and Mabel Beckman Foundation, the American Cancer Society for an Institutional Research Grant (IRG-58-001-40-IRG-19), the American Chemical Society-Petroleum Research Fund (ACS-PRF#33953-G1) and the National Institute of General Medical Sciences (1R01 GM63150-01A1) for their generous support of our program. Funding by the National Science Foundation (NSF-EPSCoR award #0314742) for a Varian 600 MHz Inova Spectrometer and NMR facility is gratefully acknowledged.

### **REFERENCES AND NOTES**

- 1. This paper is dedicated to Professor Leo A. Paquette on the occasion of his 70th birthday.
- 2. University of Minnesota Undergraduate Research Opportunity Program (UROP) Participant
- For a review of dihalocyclopropane ring opening reactions, see: (a) M. G. Banwell and M. E. Reum, in 'Advances In Strain In Organic Chemistry,' Vol. 1, ed. by B. Halton, Jai Press, Inc. Greenwich, CT, 1991.

- For Lewis acid catalyzed opening of aziridines see: B. A. B. Prasad, G. Sekar, and V. K. Singh, *Tetrahedron Lett.*, 2000, 41, 4677 and references therein.
- J. U. Jeong, B. Tao, I. Sagasser, H. Henniges, and K. B. Sharpless, J. Am. Chem. Soc., 1998, 120, 6844.
- Upon completion of this work, similar stereoselectivity for this reaction were discovered in a cyclopentenol substrate, by O'Brien, see: D. Caine, P. O'Brien, and C. M. Rosser, *Org. Lett.*, 2002, 4, 1923.
- S. Winstein and J. Sonnenberg, J. Am. Chem. Soc., 1961, 83, 3235. W. von. E. Doering and A. K. Hoffmann, J. Am. Chem. Soc., 1954, 76, 6162.
- 8. We have found that freshly prepared tetrabutylammonium perbromide provided similarly good yields of **4** and **7**.
- 9. Due to the high degree of H-H *J*-coupling and the twist boat nature of **4** all nOe experiments were inconclusive in determining the relative stereochemistry between the cyclopropane and aziridine rings.
- 10. (a) J. Rudolph, K. L. Reddy, J. P. Chiang, and K. B. Sharpless, *J. Am. Chem. Soc.*, 1997, **119**, 6189.
  (b) H. Adolfsson, A. Converso, and K. B. Sharpless, *Tetrahedron Lett.*, 1999, **40**, 3991.
- L. A. Paquette, W. E. Fristad, C. A. Schuman, M. A. Beno, and C. G. Christoph, *J. Am. Chem. Soc.*, 1979, **101**, 4645.
- 12. K. Krajewski, Z. Ciunik, and I. Z. Siemion, *Tetrahedron: Asymmetry*, 1999, 10, 4591.
- 13. J. Anman, T. Jarevang, and P. Somfai, J. Org. Chem., 1996, 61, 8148.